Engineering nanocages with polyglutamate domains for coupling to hydroxyapatite biomaterials and allograft bone

Biomaterials

Volumn 34, Issue 10, 2013, Pages 2455-2462

  Culpepper, Bonnie K ^a   Morris, David S ^b   Prevelige, Peter E ^b   Bellis, Susan L ^a,c  

^a and Radiation Oncology   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bone graft; Drug delivery; Hydroxyapatite; Nanoparticle

Indexed keywords

AGAROSE; BIOACTIVE PEPTIDES; BONE GRAFT; BONE MINERALS; BONE REPAIR; COAT PROTEINS; CODING SEQUENCES; DRUG DELIVERY SYSTEM; NANOCAGES; NEW MECHANISMS; POLYGLUTAMATE; SITE DIRECTED MUTAGENESIS; WILD TYPES;

BIOLOGICAL MATERIALS; BIOMATERIALS; DRUG DELIVERY; ENZYME ACTIVITY; HYDROXYAPATITE; LOADING; NANOPARTICLES; POLYCAPROLACTONE; POLYSTYRENES; PROTEINS;

BONE;

AGAROSE; BIOMATERIAL; GLUTAMIC ACID; HYDROXYAPATITE; NANOCAGE; POLYCAPROLACTONE; POLYGLUTAMIC ACID; POLYSTYRENE;

AMINO ACID SEQUENCE; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; BONE ALLOGRAFT; CERAMICS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

BACTERIOPHAGE P22; BIOCOMPATIBLE MATERIALS; CAPSID PROTEINS; DRUG DELIVERY SYSTEMS; DURAPATITE; MUTAGENESIS, SITE-DIRECTED; NANOPARTICLES; NANOSTRUCTURES; POLYGLUTAMIC ACID;

EID: 84872674781     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.026     Document Type: Article

References (47)

1. Giannoudis P.V., Dinopoulos H., Tsiridis E. Bone substitutes: an update. Injury 2005, 36(Suppl 3):S20-S27.
2. Bostrom M.P., Seigerman D.A. The clinical use of allografts, demineralized bone matrices, synthetic bone graft substitutes and osteoinductive growth factors: a survey study. HSS J 2005, 1:9-18.
3. Nandi S.K., Roy S., Mukherjee P., Kundu B., De D.K., Basu D. Orthopaedic applications of bone graft & graft substitutes: a review. Indian J Med Res 2010, 132:15-30.
4. Ganss B., Kim R.H., Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 1999, 10:79-98.
5. Hoang Q.Q., Sicheri F., Howard A.J., Yang D.S. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 2003, 425:977-980.
6. Stayton P.S., Drobny G.P., Shaw W.J., Long J.R., Gilbert M. Molecular recognition at the protein-hydroxyapatite interface. Crit Rev Oral Biol Med 2003, 14:370-376.
7. Itoh D., Yoneda S., Kuroda S., Kondo H., Umezawa A., Ohya K., et al. Enhancement of osteogenesis on hydroxyapatite surface coated with synthetic peptide (EEEEEEEPRGDT) in vitro. J Biomed Mater Res 2002, 62:292-298.
8. Fujisawa R., Mizuno M., Nodasaka Y., Kuboki Y. Attachment of osteoblastic cells to hydroxyapatite crystals by a synthetic peptide (glu7-pro-arg-gly-asp-thr) containing two functional sequences of bone sialoprotein. Matrix Biol 1997, 16:21-28.
9. Sawyer A.A., Weeks D.M., Kelpke S.S., McCracken M.S., Bellis S.L. The effect of the addition of a polyglutamate motif to RGD on peptide tethering to hydroxyapatite and the promotion of mesenchymal stem cell adhesion. Biomaterials 2005, 26:7046-7056.
10. Sawyer A.A., Hennessy K.M., Bellis S.L. The effect of adsorbed serum proteins, RGD and proteoglycan-binding peptides on the adhesion of mesenchymal stem cells to hydroxyapatite. Biomaterials 2007, 28:383-392.
11. Culpepper B.K., Phipps M.C., Bonvallet P.P., Bellis S.L. Enhancement of peptide coupling to hydroxyapatite and implant osseointegration through collagen mimetic peptide modified with a polyglutamatetamate domain. Biomaterials 2010, 31:9586-9594.
12. Culpepper B.K., Bonvallet P.P., Reddy M.S., Ponnazhagan S., Bellis S.L. Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone. Biomaterials 2013, 34:1506-1513.
13. O'Neil A., Reichhardt C., Johnson B., Prevelige P.E., Douglas T. Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage p22. Angew Chem Int Ed Engl 2011, 50:7425-7428.
14. Qazi S., Liepold L.O., Abedin M.J., Johnson B., Prevelige P., Frank J.A., et al. P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol Pharm 2012; Jul 16, ePub ahead of print.
15. Aljabali A.A., Shukla S., Lomonossoff G.P., Steinmetz N.F., Evans D.J. CPMV-DOX delivers. Mol Pharm 2012; Aug 6, ePub ahead of print.
16. Kang S., Uchida M., O'Neil A., Li R., Prevelige P.E., Douglas T. Implementation of p22 viral capsids as nanoplatforms. Biomacromolecules 2010, 11:2804-2809.
17. Kang S., Lander G.C., Johnson J.E., Prevelige P.E. Development of bacteriophage p22 as a platform for molecular display: Genetic and chemical modifications of the procapsid exterior surface. Chembiochem 2008, 9:514-518.
18. Lanman J., Tuma R., Prevelige P.E. Identification and characterization of the domain structure of bacteriophage p22 coat protein. Biochemistry 1999, 38:14614-14623.
19. Galisteo M.L., Gordon C.L., King J. Stability of wild-type and temperature-sensitive protein subunits of the phage p22 capsid. J Biol Chem 1995, 270:16595-16601.
20. Chen D.H., Baker M.L., Hryc C.F., DiMaio F., Jakana J., Wu W., et al. Structural basis for scaffolding-mediated assembly and maturation of a dsDNA virus. Proc Natl Acad Sci U S A 2011, 108:1355-1360.
21. Phipps M.C., Clem W.C., Catledge S.A., Xu Y., Hennessy K.M., Thomas V., et al. Mesenchymal stem cell responses to bone-mimetic electrospun matrices composed of polycaprolactone, collagen I and nanoparticulate hydroxyapatite. PLoS One 2011, 6:e16813.
22. Ono I., Gunji H., Kaneko F., Saito T., Kuboki Y. Efficacy of hydroxyapatite ceramic as a carrier for recombinant human bone morphogenetic protein. J Craniofac Surg 1995, 6:238-244.
23. Ono I., Gunji H., Suda K., Kaneko F., Murata M., Saito T., et al. Bone induction of hydroxyapatite combined with bone morphogenetic protein and covered with periosteum. Plast Reconstr Surg 1995, 95:1265-1272.
24. LeBaron R.G., Athanasiou K.A. Extracellular matrix cell adhesion peptides: functional applications in orthopedic materials. Tissue Eng 2000, 6:85-103.
25. Yasuda H., Yano K., Wakitani S., Matsumoto T., Nakamura H., Takaoka K. Repair of critical long bone defects using frozen bone allografts coated with an rhBMP-2-retaining paste. J Orthop Sci 2012, 17:299-307.
26. Wang H., Leeuwenburgh S.C., Li Y., Jansen J.A. The use of micro- and nanospheres as functional components for bone tissue regeneration. Tissue Eng Part B Rev 2012, 18:24-39.
27. Low S.A., Kopecek J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 2012, 64:1189-1204.
28. Wang D., Miller S.C., Kopeckova P., Kopecek J. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 2005, 57:1049-1076.
29. Wang G., Mostafa N.Z., Incani V., Kucharski C., Uludag H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res A 2012, 100:684-693.
30. Hengst V., Oussoren C., Kissel T., Storm G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 2007, 331:224-227.
31. Cenni E., Granchi D., Avnet S., Fotia C., Salerno M., Micieli D., et al. Biocompatibility of poly(d, l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 2008, 29:1400-1411.
32. Salerno M., Cenni E., Fotia C., Avnet S., Granchi D., Castelli F., et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 2010, 10:649-659.
33. Wang G., Kucharski C., Lin X., Uludag H. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration. J Drug Target 2010, 18:611-626.
34. Thamake S.I., Raut S.L., Gryczynski Z., Ranjan A.P., Vishwanatha J.K. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012, 33:7164-7173.
35. Gil L., Han Y., Opas E.E., Rodan G.A., Ruel R., Seedor J.G., et al. Prostaglandin e2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 1999, 7:901-919.
36. Uludag H., Kousinioris N., Gao T., Kantoci D. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol Prog 2000, 16:258-267.
37. Hosain F., Spencer R.P., Couthon H.M., Sturtz G.L. Targeted delivery of antineoplastic agent to bone: Biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 1996, 37:105-107.
38. Morioka M., Kamizono A., Takikawa H., Mori A., Ueno H., Kadowaki S., et al. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem 2010, 18:1143-1148.
39. Ziebart T., Pabst A., Klein M.O., Kammerer P., Gauss L., Brullmann D., et al. Bisphosphonates: Restrictions for vasculogenesis and angiogenesis: Inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 2011, 15:105-111.
40. Kasugai S., Fujisawa R., Waki Y., Miyamoto K., Ohya K. Selective drug delivery system to bone: small peptide (asp)6 conjugation. J Bone Miner Res 2000, 15:936-943.
41. Huang L., Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011, 13:507-530.
42. Koudelka K.J., Manchester M. Chemically modified viruses: Principles and applications. Curr Opin Chem Biol 2010, 14:810-817.
43. Teschke C.M., McGough A., Thuman-Commike P.A. Penton release from p22 heat-expanded capsids suggests importance of stabilizing penton-hexon interactions during capsid maturation. Biophys J 2003, 84:2585-2592.
44. Jiang W., Li Z., Zhang Z., Baker M.L., Prevelige P.E., Chiu W. Coat protein fold and maturation transition of bacteriophage p22 seen at subnanometer resolutions. Nat Struct Biol 2003, 10:131-135.
45. Uchida M., Morris D.S., Kang S., Jolley C.C., Lucon J., Liepold L.O., et al. Site-directed coordination chemistry with p22 virus-like particles. Langmuir 2012, 28:1998-2006.
46. Lucon J., Qazi S., Uchida M., Bedwell G.J., Lafrance B., Prevelige P.E., et al. Use of the interior cavity of the p22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat Chem 2012, 4:781-788.
47. Cortines J.R., Weigele P.R., Gilcrease E.B., Casjens S.R., Teschke C.M. Decoding bacteriophage p22 assembly: Identification of two charged residues in scaffolding protein responsible for coat protein interaction. Virology 2011, 421:1-11.